In a historic first, the US Food and Drug Administration (FDA) has approved SYFOVRE (pegcetacoplan injection), manufactured by global biopharmaceutical...
Read moreMyopia Profile has launched a first-of-its-kind online course on myopia management with spectacles to help deliver treatment to more children...
Read moreAustralian eyecare professionals wanting to elevate their dry eye management and treat inflammation can access the latest intense pulse light...
Read moreGlaucoma is estimated to cost Australia $4.3 billion every year by 2025,¹ as a result of an ageing population. Approximately...
Read moreNewly released research findings support a potential new treatment option for dry eye disease associated with meibomian gland dysfunction (MGD)...
Read moreAt the completion of this article, the reader should be able to align their clinical protocols more closely to a...
Read moreThe treatment landscape for wet and dry AMD is undergoing a seismic shift in Australia. CERA’s head of macular research...
Read moreClinical-stage biopharmaceutical company Azura Ophthalmics, which operates out of Melbourne and Tel Aviv, has reported positive three-month results for its...
Read moreA home-based, non-invasive sleep mask to treat diabetic retinopathy has been adopted by a hospital network within the UK’s National...
Read moreA panel of experts assembled by HOYA Vision Care have shared their consensus on the effectiveness of combining spectacle lenses...
Read moreInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited